Viking Therapeutics (NASDAQ:VKTX – Get Free Report) had its price objective raised by research analysts at Oppenheimer from $116.00 to $138.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 65.27% from the company’s previous […]